CoChat

Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: III. Discontinuation Effects

Pecknold, John C. · 1988 · Archives of General Psychiatry

The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.

Abstract

Preliminary reports of discontinuation of alprazolam therapy in patients with panic disorder have revealed worsening of symptoms despite gradual withdrawal of medication. In this study, 126 patients with panic disorder and phobic avoidance received either alprazolam or placebo in doses of 2 to 10 mg daily for eight weeks. The medication was tapered over a period of four weeks, and patients were observed for another two weeks after all medication was discontinued. Sixty of the 63 alprazolam-treated patients and 49 of the 63 placebo-treated patients entered the taper and discontinuation study. After improvement in the active treatment period, the alprazolam-treated group had significant relapse between the first and last week of taper. However, during the second postdiscontinuation week, outcome scores were not significantly different from those of the placebo-treated group who did not deteriorate during taper. Twenty-seven percent of the alprazolam-treated group reported a rebound of panic attacks during taper and 13% reported a rebound of anxiety on the Hamilton Anxiety Scale. No serious or life-threatening withdrawal symptoms were reported, but distinct, transient, mild to moderate withdrawal syndrome occurred in 35% of the alprazolam-treated group and in none of the placebo-treated group. The coexistence of symptom rebound and a withdrawal syndrome occurred in 10% of the alprazolam-treated group, but both subsided by the end of the second week without alprazolam. We recommend that patients with panic disorder be treated for a longer period, at least six months, and that medication be tapered over a more prolonged period, at least eight weeks, especially where high doses are employed.

Overview

Integrity signals

Registry

Crossref · 10.1001/archpsyc.1988.01800290043006

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 83 references

Cited by

See all 222

Metadata

Authors
Pecknold, J. C.
Affiliations
McGill University (CA)
Corresponding author
Pecknold, John C.
Venue
Archives of General Psychiatry
Published
1988-05-01
Volume
45
Issue
5
Pages
429
ISSN
0003-990X (ISSN-L)
OpenAlex
W2063100289
Cited by
204
References
82
Citations by year
2025: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2020: 2 · 2019: 5 · 2017: 4 · 2016: 1 · 2015: 3 · 2013: 1 · 2012: 2
FWCI
34.29
Type
journal article
Language
en
Open access
closed
Locations
  • Archives of General Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
  • Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
Keywords
alprazolam, panic disorder, agoraphobia, benzodiazepines, medication tapering, drug discontinuation, withdrawal syndrome, relapse, phobic avoidance, treatment duration
MeSH terms
Adult, Alprazolam, Anxiety Disorders, Clinical Trials as Topic, Drug Administration Schedule, Fear, Female, Humans, Male, Outcome and Process Assessment, Health Care, Panic, Personality Inventory, Placebos, Psychiatric Status Rating Scales, Recurrence, Substance Withdrawal Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: III. Discontinuation Effects. https://app.cochat.ai/papers/10.1001/archpsyc.1988.01800290043006
The paper
Pecknold, J. C. (1988). Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: III. Discontinuation Effects. Archives of General Psychiatry. https://doi.org/10.1001/archpsyc.1988.01800290043006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.